Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 6/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | TEK | Q02763 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14949193 | 0.88 | KDR (0.51) | GSK3BACHEFGFR2KDRPDGFRA | |
| SCHEMBL12336407 | 0.86 | GSK3B (0.53) | GSK3BACHEFGFR2KDRPDGFRA | |
| SCHEMBL14949497 | 0.83 | MET (0.46) | FGFR2KDRPDGFRAAURKAMET | |
| SCHEMBL14949327 | 0.81 | KDR (0.48) | GSK3BACHEFGFR2KDRPDGFRA | |
| SCHEMBL12336429 | 0.80 | KDR (0.49) | GSK3BKDRAURKAMETTEK | |
| SCHEMBL14949195 | 0.78 | MEN1 (0.48) | GSK3BACHEFGFR2KDRPDGFRA | |
| SCHEMBL12336252 | 0.76 | KDR (0.60) | GSK3BFGFR2KDRFLT1IDO1 | |
| SCHEMBL17339773 | 0.72 | BRAF (0.41) | FGFR2KDRMETTEK | |
| SCHEMBL14949392 | 0.71 | KDR (0.49) | FGFR2KDRPDGFRAAURKAMET | |
| SCHEMBL13547760 | 0.70 | GSK3B (0.39) | GSK3BACHEPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | MAP4K2, MAP3K20, MAP3K19 | GSK3B 581/4885ACHE 4684/4885FGFR2 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.